Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924469 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00924469 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 58 participants.
The verdict
NCT00924469, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors) who are suitable candidates for prostatectomy (surgery to remove all or part of the prostate gland).
Interventions
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Leuprolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924469
The ClinicalTrials.gov registry entry for NCT00924469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT00924469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924469 about?
NCT00924469 is a clinical study titled "A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer". The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, form...
What is the current status of trial NCT00924469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2009-11. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00924469?
The interventions under investigation include: Prednisone (DRUG), Abiraterone (DRUG), Leuprolide (DRUG).
Who is sponsoring clinical trial NCT00924469?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.